Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

Inclusion Criteria: * Provision of signed and dated informed consent form * A resting SpO2 of \>93% on room air. * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 18 and over, presenting with mild to moderate clinical symptoms of Covid- 19 infection (per FDA guidance - see appendix 3) with symptom onset within 5 days prior to the day of randomization * Positive COVID-19 infection confirmed by RT-PCR within the last 5 days of the day of randomization * A score of ≥ 2 (moderate) on a minimum of 1 symptom on the PRO Symptom Survey on the day of randomization * Ability to take oral medication and be willing to adhere to the dosing regimen (Twice a day - BID for 14 days) * For females of reproductive potential: negative pregnancy test at screening and use of highly effective contraception method during study participation and for an additional 4 weeks after the end of study drug administration * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of study drug administration * Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration * To be considered high risk, participants should have at least one of the following conditions: * age ≥60 years; * active cancer * chronic kidney disease; * chronic lung disease including COPD * O…